Table 4.
Distribution of ER, PR, and HER2 status according to biopsied site.
| Sites of biopsy | Total | Change in ER | Change in PR | Change in HER2 status | |||
|---|---|---|---|---|---|---|---|
| DiscordantN (%) | ConcordantN (%) | DiscordantN (%) | ConcordantN (%) | DiscordantN (%) | ConcordantN (%) | ||
| Locoregional lesions | 45 | 12 (26.7%) | 33 (73.3%) | 18 (40.0%) | 27 (60.0%) | 9 (20.0%) | 36 (80.0%) |
| Metastasis lesions | 22 | 6 (27.3%) | 16 (72.7%) | 8 (36.4%) | 14 (63.6%) | 6 (27.3%) | 16 (72.7%) |
| Lung | 8 | 3 (37.5%) | 5 (62.5%) | 2 (25.0%) | 6 (75.0%) | 2 (25.0%) | 6 (75.0%) |
| Liver | 4 | 0 | 4 (100%) | 0 | 4 (100%) | 1 (25.0%) | 3 (75.0%) |
| Bone | 2 | 1 (50%) | 1 (50%) | 1 (50%) | 1 (50%) | 0 | 2 (100%) |
| MLN | 1 | 0 | 1 (100%) | 1 (100%) | 0 | 1 (100%) | 0 |
| Others | 7 | 2 (28.6%) | 5 (71.4%) | 4 (57.1%) | 3 (42.9%) | 2 (28.6%) | 5 (71.4%) |
MLN: Mediastinal lymph nodes.